Drugs / IOMETOPANE
IOMETOPANE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00273351 | Jan 2006 → Jan 2008 | Parkinson disease | Institute for Neurodegenerative Disorders | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IOMETOPANE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110676 ↗ |
| Known as | [123I]B-CIT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00273351 ↗ |
| Known as | Beta-CIT | “The biomarkers in this study include brain imaging with a radioactively labelled drug (Beta-CIT), computerized testing of memory, attention, motor speed, judgment and...” NCT00273351 ↗ |
| Known as | Iometopano (123i) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110676 ↗ |
| Known as | RTI 4229-98 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110676 ↗ |
| Known as | RTI 55 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110676 ↗ |
| Modality | Diagnostic / imaging agent | “brain imaging with a radioactively labelled drug (Beta-CIT)” NCT00273351 ↗ |
| Route | Intravenous | “injected intravenously” NCT00273351 ↗ |